——掃描上方二維碼，報(bào)名參會(huì)—

過去十年，中國創(chuàng)新藥研發(fā)管線數(shù)量呈現(xiàn)爆發(fā)式增長，已成為全球新藥研發(fā)體系中不可或缺的一環(huán)。在雙特異性抗體、ADC等前沿技術(shù)領(lǐng)域，中國已形成具備全球競爭力的研發(fā)集群，持續(xù)推動(dòng)跨境交易活躍增長。2025年，中國創(chuàng)新藥對(duì)外許可總額突破1000億美元，達(dá)2024年同期的兩倍。然而，目前僅有約10%的新藥管線進(jìn)入交易視野，更多高價(jià)值資產(chǎn)仍待全球合作伙伴共同發(fā)掘。

中國創(chuàng)新藥的崛起并非偶然，而是政策引導(dǎo)、人才集聚、資本支持與產(chǎn)業(yè)升級(jí)共同驅(qū)動(dòng)的必然結(jié)果。這一體系性優(yōu)勢，使中國在新藥研發(fā)效率、臨床執(zhí)行能力及前沿賽道布局方面展現(xiàn)出卓越潛力。

在此關(guān)鍵歷史時(shí)刻，）肩負(fù)使命，將于2026年JPM大會(huì)期間，隆重主辦“2026中國FIC創(chuàng)新與合作峰會(huì)” 。這不僅僅是一場會(huì)議，更是一次中國生物科技力量的集體亮相，一個(gè)為全球伙伴精心打造的頂級(jí)合作平臺(tái)。

本屆峰會(huì)將系統(tǒng)解讀中國創(chuàng)新藥的發(fā)展動(dòng)因、現(xiàn)狀與未來趨勢，并精選一批在全球范圍內(nèi)具有領(lǐng)先研發(fā)進(jìn)度、高度臨床契合度及顯著交易價(jià)值的創(chuàng)新藥項(xiàng)目進(jìn)行路演，為與會(huì)者提供評(píng)估中國創(chuàng)新實(shí)力、發(fā)掘高價(jià)值合作機(jī)遇的重要窗口。

主辦機(jī)構(gòu)：ZFIC聯(lián)盟

時(shí)間：2026年1月11日

地點(diǎn)：美國加州舊金山市中心凱悅酒店

會(huì)議人數(shù)：400人

參會(huì)形式：免費(fèi)報(bào)名+審核、邀約

—會(huì)議酒店掠影—

活動(dòng)日程

Event Agenda

09:00-09:20 致辭

09:20-09:40主題演講

從監(jiān)管視角看中國生物醫(yī)藥創(chuàng)新的演變歷程

李自力 博士，國際藥物信息協(xié)會(huì)（DIA）全球董事，ZFIC聯(lián)盟戰(zhàn)略顧問

09:40-10:20主題演講

中國生物科技創(chuàng)新的全球趨勢

10:10-10:20 茶歇

自由交流

10:20-10:40 主題演講

中國創(chuàng)新藥對(duì)外授權(quán)交易趨勢與數(shù)據(jù)洞察

李昕欣，醫(yī)藥魔方海外市場首席顧問

10:40-11:00 主題演講

小核酸創(chuàng)新藥的中國力量

鐘輝，堯景基因首席科學(xué)家

11:00-12:00圓桌討論

中國FIC管線的創(chuàng)新前沿展望

12:00-13:00 自助午餐

13:10-13:20 ZFIC聯(lián)盟介紹

13:20-13:40主題演講

創(chuàng)新藥生態(tài)的“通關(guān)指南”：人才、政策與資本的高效協(xié)同

13:40-14:00 主題演講

高質(zhì)量臨床試驗(yàn)支持原創(chuàng)藥物開發(fā)：全球首款心肌梗死抗體藥物SGC001的實(shí)踐

孟玲，舜景醫(yī)藥副總經(jīng)理

14:00-16:30 項(xiàng)目路演

• Targeting GSDME: A First-in-Class Mechanism to Block Inflammatory Neuronal Death in ALS and Beyond

  炎明生物

• KN060, A phase II stage potential BIC anti-FXI bispecific antibody

  康寧杰瑞

• A Potential First-in-Class Bispecific Antibody as A Backbone Immunotherapy

  熱景生物

• JV101: Redefining Heart Failure Treatment with a One-Time, Broadly Effective Gene Therapy

  愈方生物

• FL115: A Next-Generation Engineered IL-15 Therapy Designed for Streamlined Efficacy and Optimal Synergy in Combination Immunotherapy

  復(fù)融生物

• KC1086: A First-in-Class and Differentiated Dual KAT6/7 Inhibitor with Superior Preclinical Profile for Resistant ER+ Breast Cancer

  康辰藥業(yè)

• NouvNeu001:the 1st chemical derived cell therapeutic product in the World

  睿健醫(yī)藥

• YN001: An Actively Targeted Therapy Demonstrating Direct Atherosclerotic Plaque Regression in Clinical Trials

  茵諾醫(yī)藥

• GS1191: A Potentially Best-in-Class Hemophilia A Gene Therapy with Superior Efficacy at a lower Dose

  華毅樂健

16:30-17:15圓桌討論

尋找下一個(gè)重磅藥物：立項(xiàng)、速度與價(jià)值

17:15-18:00圓桌討論

攜手向前：構(gòu)建創(chuàng)新藥全球新生態(tài)

活動(dòng)亮點(diǎn)

Event Highlights

中國創(chuàng)新生態(tài)系統(tǒng)全景透視：FIC創(chuàng)新藥戰(zhàn)略發(fā)展聯(lián)盟（ZFIC Alliance）首次海外亮相，從監(jiān)管視角解讀中國創(chuàng)新生態(tài)系統(tǒng)質(zhì)變，以數(shù)據(jù)呈現(xiàn)中國創(chuàng)新藥管線版圖和跨境交易趨勢，幫助海外藥企和投資機(jī)構(gòu)更加系統(tǒng)深入地理解中國創(chuàng)新藥產(chǎn)業(yè)。

高質(zhì)量國際交流：參會(huì)觀眾中，海外公司占比70%，國內(nèi)公司30%。藥企VP以上管理層和機(jī)構(gòu)合伙人占比70%，云集 輝瑞、葛蘭素史克、吉利德、 拜耳、 默克、武田制藥、 百濟(jì)神州、 復(fù)宏漢霖、恒瑞醫(yī)藥、科倫博泰、RA Capital等知名藥企和投資機(jī)構(gòu)。

高潛力項(xiàng)目路演：ZFIC聯(lián)盟專家組從近30個(gè)申報(bào)公司項(xiàng)目中優(yōu)選8個(gè)匹配臨床未滿足需求、具有較高創(chuàng)新水平且研發(fā)進(jìn)度領(lǐng)先、具有FIC和BIC成藥潛力的代表性中國創(chuàng)新藥項(xiàng)目，進(jìn)行現(xiàn)場路演，幫助海外藥企和投資機(jī)構(gòu)更高效地發(fā)掘中國創(chuàng)新藥優(yōu)質(zhì)資產(chǎn)。

—掃碼報(bào)名參會(huì)—

2026 China FIC Innovation and

Collaboration Summit

Over the past decade, the number of innovative drug pipelines in China has experienced explosive growth and has become an important part of the global innovative drug landscape. In the meanwhile, transaction activities over Chinese innovative drugs have continued to be active, with cross-border transactions emerging continuously. In particular, China has formed R&D clusters with global competitiveness in emerging technology fields such as bispecific antibodies and ADCs. In 2025, the total amount of cross-border licensing of Chinese innovative drugs exceeded 100 billion US dollars, doubling the scale of the same period in 2024. Even so, only about 10% of the new drug pipelines in China have been involved in transactions. More high-value tradable pipeline assets are still waiting to be explored for cooperation with global partners.

In light of this, the FIC Innovative Drug Strategic Development Alliance (ZFIC Alliance) will hold the "2026 China FIC Innovation and Collaboration Summit" during the 2026 JPM Conference, aiming to build an efficient communication platform for international pharmaceutical companies, investment institutions, and Chinese biotech enterprises.

This summit will provide a comprehensive data-driven interpretation of driving factors, current status, and future trends of Chinese innovative drugs’ explosive growth, and offering participants a full and authentic view of the Chinese innovative drug landscape. In addition, the summit will organize roadshows for a number of selected Chinese innovative drug pipelines of globally leading development status, critical clinical relevance, and significant underlying transaction values. The event will be a window to discover high-value strategic cooperation opportunities over China's most innovative therapeutic assets.

Time: January 11, 2026

Venue: Hyatt Regency San Francisco Downtown SOMA

Agenda

8:30-9:00 Registration

9:00-9:20 Opening Remarks

9:20-9:50 Keynote Speech

Understanding the Evolution of China’s Biotech Innovation: A Regulatory Perspective

Zili Li, MD MPH，DIA Fellow and Board Member Strategic Advisor to ZFIC Alliance

9:50-10.10 Keynote Speech

Trends in China's Biotech Innovation

10:10-10:20 Coffee Break

10:20-10:40 Keynote Speech

Trends and Data Insights of China's Innovative Drug Out-Licensing Transactions

Xinxin Li，Principal Advisor, Pharmcube

10:40-11:00 Keynote Speech

Highlights of China’s innovation in Oligonucleotide Innovative Drugs

Dr. Joann Zhong, CSO, Beijing Youngen Biotechnology Co., Ltd.

11:00-12:00 Panel Discussion

Outlook of China's FIC Pipeline

12:00-13:20 Buffet Lunch

13:20-13:40 Keynote Speech

The "Rulebook" for the Innovative Drug Ecosystem: Efficient Synergy of Talent, Policy, and Capital

13:40-14:00 Keynote Speech

High-Quality Clinical Trials Underpinning Innovative Drug Development: Development of SGC001, the First-in-World Antibody for Myocardial Infarction

Dr. Ling Meng, Vice President, Beijing Sungen Biomedical Technology Co., Ltd.

14:00-16:30 Roadshow

• Targeting GSDME: A First-in-Class Mechanism to Block Inflammatory Neuronal Death in ALS and Beyond

  Pyrotech Therapeutics

• KN060, A phase II stage potential BIC anti-FXI bispecific antibody

  Suzhou Alphamab Co., Ltd.

• A Potential First-in-Class Bispecific Antibody as A Backbone Immunotherapy

  Hotgen

• JV101: Redefining Heart Failure Treatment with a One-Time, Broadly Effective Gene Therapy

  Shanghai Yufang Biopharmaceutical Technology

• FL115: A Next-Generation Engineered IL-15 Therapy Designed for Streamlined Efficacy and Optimal Synergy in Combination Immunotherapy

  Forlong Biotech

• KC1086: A First-in-Class and Differentiated Dual KAT6/7 Inhibitor with Superior Preclinical Profile for Resistant ER+ Breast Cancer

  Beijing Konruns Pharmaceutical

• NouvNeu001:the 1st chemical derived cell therapeutic product in the World

• iRegene Therapeutics

• YN001: An Actively Targeted Therapy Demonstrating Direct Atherosclerotic Plaque Regression in Clinical Trials

• Beijing Inno Medicine Co., Ltd.

• GS1191: A Potentially Best-in-Class Hemophilia A Gene Therapy with Superior Efficacy at a lower Dose

• Gritgen Therapeutics

16:30-17:15 Panel Discussion

Finding the Next Blockbuster Drug: Project Planning, Speed, and Value

17:15-18:00 Panel Discussion

Moving Forward Together: Building a New Global Ecosystem for Innovative Drugs